1	Differential antibody production by symptomatology in SARS-CoV-2
2	convalescent individuals
3	
4	Sharada Saraf ¹ , Xianming Zhu ² , Ruchee Shrestha ² , Tania S. Bonny ^{2§} , Owen R. Baker ³ , Evan J.
5	Beck ¹ , Reinaldo E. Fernandez ³ , Yolanda Eby ² , Olivia Akinde ² , Jessica E. Ruff ² , Patrizio
6	Caturegli ² , Andrew D. Redd ^{1,3} , Evan M. Bloch ² , Thomas C. Quinn ^{1,2,3} , Aaron AR Tobian ^{2,3,4} ,
7	Oliver Laeyendecker ^{1,3*}
8	
9 10	¹ Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
11	² Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
12 13	³ Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
14 15	⁴ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
16	[§] Current Affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
17	
18	*Corresponding Author:
19 20 21 22 23	Oliver Laeyendecker 855 North Wolfe Street Rangos Building, Room 538A Baltimore, MD 21205 Email: <u>olaeyen1@jhmi.edu</u>
24	
25	Conflict of interest statement
26	The authors have declared that no competing interests exist
27	

28 Abstract

29	The association between COVID-19 symptoms and antibody responses against SARS-CoV-2 is
30	poorly characterized. We analyzed antibody levels in individuals with known SARS-CoV-2
31	infection to identify potential antibody-symptom associations. Convalescent plasma from 216
32	SARS-CoV-2 RNA+ individuals with symptomatology information were tested for the presence
33	of IgG to the spike S1 subunit (Euroimmun ELISA), IgG to receptor binding domain (RBD,
34	CoronaCHEK rapid test), and for IgG, IgA, and IgM to nucleocapsid (N, Bio-Rad ELISA).
35	Logistic regression was used to estimate the odds of having a COVID-19 symptom from the
36	antibody response, adjusting for sex and age. Cough strongly associated with antibodies against
37	S1 (adjusted odds ratio [aOR]= 5.33; 95% CI from 1.51 to 18.86) and RBD (aOR=4.36; CI 1.49,
38	12.78). In contrast, sore throat significantly associated with the absence of antibodies to S1 and
39	N (aOR=0.25; CI 0.08, 0.80 and aOR=0.31; 0.11, 0.91). Similarly, lack of symptoms associated
40	with the absence of antibodies to N and RBD (aOR=0.16; CI 0.03, 0.97 and aOR=0.16; CI 0.03,
41	1.01). Cough appeared to be correlated with a seropositive result, suggesting that SARS-CoV-2
42	infected individuals exhibiting lower respiratory symptoms generate a robust antibody response.
43	Conversely, those without symptoms or limited to a sore throat while infected with SARS-CoV-2
44	were likely to lack a detectable antibody response. These findings strongly support the notion
45	that severity of infection correlates with robust antibody response.
46	

- 47
- 48
- 49
- 50

51 Introduction

52	The ongoing COVID-19 pandemic has challenged health care systems globally and
53	necessitated rapid deployment of treatments and vaccines. SARS-CoV-2 infection, the causative
54	agent of COVID-19, elicits a broad range of symptoms: fever, cough, shortness of breath, and
55	myalgia are the most reported symptoms among critically ill patients. ¹ Antibody levels serve as a
56	potential correlate of protection against COVID-19; individuals who test positive for anti-spike
57	and anti-nucleocapsid IgG antibodies have demonstrated a substantially reduced risk of SARS-
58	CoV-2 reinfection. ² Moreover, high vaccine-induced antibody responses are associated with
59	lower risk of symptomatic COVID-19. ³
60	Previous studies have observed higher prevalence of seroconversion among severely ill
61	individuals versus those with asymptomatic or mild disease. ⁴ Additionally, studies have shown
62	that males, older individuals, and those previously hospitalized with symptoms generate strong
63	antibody responses. ⁵ SARS-CoV-2 antibody levels have been demonstrated to positively
64	correlate with the severity of COVID-19; however, the immune responses of individuals
65	experiencing milder disease remain poorly characterized. ⁶⁻⁸ Investigating possible correlations
66	with symptomatology can add more nuance to characterizing population level immunity or
67	seroprevalence in a certain population, thus informing future public health interventions. ^{7,9}
68	Furthermore, these data may help inform whether previously infected individuals have a higher
69	chance of re-infection depending on their symptom presentation during their disease course,
70	which can better characterize the urgency of vaccination in these individuals. ^{10,11}
71	We investigated whether certain symptoms are predictive of a stronger antibody response by
72	analyzing the antibody levels of individuals with known SARS-CoV-2 infection for associations
73	between antibody response and reported symptoms. Samples from individuals who recovered

from SARS-CoV-2 infection were tested for the presence of IgG antibodies to spike (S1), IgG
antibodies to the receptor binding domain (RBD), and total antibodies to nucleocapsid (N).

76

77 Materials and Methods

78 Study Participants

79 This study used stored samples and data from studies that were approved by The Johns

80 Hopkins University School of Medicine Institutional Review Board. All study participants

81 provided written informed consent and were de-identified prior to laboratory testing.

82 To assess the antibody levels of SARS-CoV-2 infected individuals, samples from 216

83 participants from the Baltimore/Washington DC area who were screened to donate COVID-19

84 convalescent plasma (CCP) and had accompanying symptom data from April 2020-January 2021

85 were evaluated.^{5,12,13} All were at least 18 years old and met the eligibility criteria for blood

86 donation.

87

88 Ascertainment of the symptomatology

As a part of a phone screening, participants were asked by a study team member if they were hospitalized and/or experienced any symptoms during their illness and, if so, to list their symptoms. Participant answers were then recorded by the screener according to 17 standard categories: no symptoms, fever, cough, chills, shortness of breath, diarrhea, fatigue, anosmia, dysgeusia, sore throat, headache, muscle ache, runny nose, stuffy nose, nausea, vomiting, or other.

95

96 Laboratory Methods

97 Plasma was separated from whole blood within 12 hours of collection and stored at -80°C

- 98 until further testing. Samples were analyzed using three commercially available serologic assays:
- 99 Euroimmun Anti-SARS-CoV-2 ELISA (Mountain Lakes, NJ), the CoronaCHEK™ COVID-19
- 100 IgG/IgM Rapid Test Cassette (Hangzhou Biotest Biotech Co Ltd), and the Bio-Rad Platelia
- 101 SARS-CoV-2 Total Antibody ELISA (Marnes-la-Coquette, France). The Euroimmun ELISA
- 102 measures IgG responses to the SARS-CoV-2 S1 protein, whereas the CoronaCHEK rapid test
- 103 measures IgG responses to the SARS-CoV-2 RBD.^{14,15} The Bio-Rad ELISA measures total
- 104 antibody response to the SARS-CoV-2 N.¹⁶
- 105 Thirty-five cytokine and chemokine analytes in plasma were assessed using a multi-array
- 106 electrochemiluminescence detection technology (MesoScale Discovery, Gaithersburg, MD) as
- 107 previously described.¹⁷ Analytes with \geq 80% overall detectability were evaluated for cytokine
- 108 level differences between symptom groups and included Eotaxin, Eotaxin-3, IFN-y, IL-
- 109 12/IL23p40, IL-15, IL-16, IL-17A, IL-18, IL-1RA, IL-6, IL-7, IL-8, IP-10, MCP-1, MCP-4,
- 110 MDC, MIP-1B, TARC, TNF-a, and VEGF-A. Analytes with <80% overall detectability were
- 111 evaluated for percent detectability differences between symptom groups and included IL-12p70,

112 IL-13, IL-1B, IL-2, IL-4, G-CSF, IFN-a2a, IL-21, IL-33, IL-8(HA), MIP-1a, GM-CSF, IL-1a,

- 113 IL-5, and TNF-B. All assays were performed according to the manufacturer's protocols.
- 114

115 **Statistical Analysis**

Binomial logistic regressions were performed to calculate odds ratios [OR] for associations between serological results and reported symptoms. Adjusted odds ratios [aOR] were calculated for all symptoms. Based on previous studies linking sex and age to antibody reactivity, these

- 119 were considered to be confounding variables and therefore included in adjusted models.⁵
- 120 Adjusted odds ratios with a p<0.05 were considered significant. All analysis were performed in
- 121 STATA v.14.2 (College Station, TX).
- 122

123 **Results**

- 124 Participants were a median age of 49 years (IQR 37-58) at the time of sample collection. This
- subject pool was 81.9% White, 9.7% Black, 4.2% Asian, and 4.2% mixed/other/unknown (Table
- 126 1). A median of 49 days (IQR 40-64) had elapsed since participants had a confirmed SARS-
- 127 CoV-2 diagnosis via detectable RNA.
- 128

129 Table 1. Demographic data of convalescent plasma donors

	All	Female	Male
Number of individuals	216	137	79
Median age (IQR)	49 (37-58)	49 (37-57)	49 (38-61)
Age categories			
19-44	85	54	31
45-64	106	69	37
65+	25	14	11
Race/ethnicity			
White	177	111	66
Black	21	15	6
Asian	9	7	2
Other	9	4	5
Median days post PCR+ blood collection (IQR)	49 (40-64)	54 (42-75)	43 (38-58)

- 130 Abbreviations: IQR, inter quartile range
- 131

132 Of the 17 different categories, the most frequently reported were fatigue (53%), fever (50%),

- 133 and cough (50%) (Fig 1). Headache (44%), muscle ache (43%), loss of smell (38%), altered taste
- 134 (33%), short breath (26%), stuffy nose (25%), and sore throat (20%) were also commonly

135	reported. Chills (16%), diarrhea (15%), nausea (9%), runny nose (8%), no symptoms (5%), and
136	vomiting (3%) were the least recorded categories. Hospitalization occurred in 7% of all
137	participants. Individuals reporting fatigue also commonly reported headache (29%), fever (26%),
138	cough (26%), and muscle ache (26%).
139	
140	Figure 1. Frequency and Correlation of COVID-19 Symptoms
141 142 143	Percentage of individuals with the symptoms or pairs of symptoms are presented. Symptom or symptom pairs prevalent in $>10\%$ of individuals are colored.
144	For each of the three serologic assays, >83% of all samples had a positive result. All
145	individuals who were hospitalized had reactive plasma to the Euroimmun ELISA,
146	CoronaCHECK (IgG) rapid test, and Bio-Rad ELISA. For individuals reporting shortness of
147	breath reactivity on Euroimmun, CoronaCHECK IgG, and Bio-Rad assays were positive on
148	93%, 91%, and 86% respectively. Other symptoms had similar consistency in reactivity, with
149	fever and cough specifically demonstrating a similar range of percent reactivity (88-94%) across
150	the three assays. Similarly, lack of reactivity to these two assays appeared to be consistent, with
151	the exception of vomiting. Lack of symptoms (40-60%) and sore throat (73-75%) demonstrated
152	relative stability across all three assays.
153	
154	Figure 2. Reactivity of Antibody Assays by Presenting Symptoms
155 156 157	Percent reactivity was calculated by dividing the number of individuals with positive antibody results reporting the indicated symptom by the total number of individuals reporting the

indicated symptom. 158 159

160	Signal to cut-off ratios (S/C) were generated for the Euroimmun and BioRad ELISAs. These
161	results were stratified by five 5 symptom categories: cough, sore throat, no symptoms, and other
162	symptoms. For the Bio-Rad assay, individuals reporting cough or other symptoms had the
163	highest mean S/C ratio. Sore throat and no symptoms had the lowest mean S/C ratio. Similarly,
164	the highest S/C ratios on the Euroimmun assay were generated by samples from individuals
165	reporting cough, other symptoms, sore throat, and no symptoms.
166	
167 168 169	Fig 3. Antibody Reactivity to Nucleocapsid Protein as measured by Bio-Rad ELISA and S1 Protein as measured by Euroimmun ELISA Stratified by Symptom Category.
170 171 172	Solid horizontal lines represent the mean S/C ratio for the indicated symptom group. Dashed horizontal line represents the positive result threshold for the indicated assay.
173	Individuals reporting cough had the strongest association with a positive antibody response to
174	S1 (aOR=5.33; 95% CI 1.51, 18.86) and RBD (aOR=4.36; CI 1.49, 12.78) though not to N
175	(Table 2). In contrast, sore throat was significantly associated with a lack of detectable antibody
176	response to S1 and N (aOR=0.25; CI 0.08, 0.80 and aOR=0.31; 0.11, 0.91), respectively.
177	Reporting a lack of symptoms was associated with a lack of antibody response to N (aOR=0.16;
178	CI 0.03, 0.97) and to RBD, though this association did not reach a statistical significance of
179	<0.05 (aOR=0.16; CI 0.03, 1.01). Individuals reporting diarrhea demonstrated decreased
180	reactivity to N (aOR=0.17; CI 0.05, 0.62), whereas stuffy nose displayed increased reactivity to
181	N (aOR=5.07; CI 0.93, 27.71). Notably, aORs and confidence intervals did not significantly
182	attenuate after adjustment across assays for cough, sore throat, or no symptoms.
183	

Table 2. Association between symptoms and antibody reactivity to S1, RBD and N proteins of SARS-CoV-2 among infected individuals

	Euroimmun IgG S1 Positive Result ²		CoronaCHEK RBD Positive Result ²		BioRad Total Ab N Positive Result ²	
Variable ¹	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ³	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ³	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ³
Cough (n=110)	5.82 (2.12,	5.33 (1.51,	5.82 (2.19,	4.36 (1.49,	1.97 (0.89,	1.51 (0.55,
Cough (II-110)	16.0) ‡	18.86) ‡	12.7) ‡	12.78) ‡	4.36)	4.13)
Altered taste (n=72)	1.59 (0.64,	0.68 (0.14,	3.52 (1.31,	3.48 (0.82,	1.44 (0.61,	0.75 (0.18,
Altered taste $(II - 72)$	3.93)	3.26)	9.53) †	14.82)	3.42)	3.17)
Sore Throat (n=45)	0.28 (0.12,	0.25 (0.08,	0.43 (0.19,	0.48 (0.16,	0.39 (0.17,	0.31 (0.11,
501e 11110at (11–45)	0.66) ‡	0.80) †	0.94) †	1.38)	0.87) †	0.91)†
Muscle ache (n=92)	1.67 (0.72,	1.87 (0.63,	2.45 (1.09,	2.25 (0.83,	1.58 (0.70,	2.23 (0.79,
Muscle ache (11–92)	3.88)	5.49)	5.51) †	6.09)	3.55)	6.26)
Diarrhea (n=33)	0.81 (0.28,	0.33 (0.08,	1.10 (0.39,	0.77 (0.19,	0.53 (0.21,	0.17 (0.05,
Diattilea (II-55)	2.29)	1.39)	3.07)	2.67)	1.37)	0.62) ‡
Stuffy nose (n=39)	0.78 (0.29,	1.55 (0.41,	0.86 (0.35,	0.83 (0.25,	3.48 (0.79,	5.07 (0.93,
Sturry nose (II-39)	2.08)	5.84)	2.14)	2.77)	15.26)	27.71) †
No symptoms $(n-10)$	0.20 (0.05,	0.24 (0.04,	0.11 (0.03,	0.16 (0.03,	0.22 (0.06-	0.16 (0.03,
No symptoms (n=10)	0.75)†	1.49)	0.41) ‡	1.01)	0.82) †	0.97) †

¹Symptoms with no significant association with antibody reactivity found: fatigue (n=115), fever (n=111), headache (n=95), anosmia (n=83), shortness of breath (n=57), chills (n=35), nausea (n=20), runny nose (n=18), vomiting (n=7), other (n=23). ²Abbreviation: S1, spike protein subunit 1; RBD, receptor binding domain; N, nucleocapsid; CI, confidence interval; n, number. ³Variables in the adjusted model included sex, age, and all symptom predictor variables. † p < 0.05, ‡ p < 0.01.

184

185 To further investigate the seronegativity of individuals reporting sore throat, individuals were

186 grouped into three categories: whether they reported no symptoms, reported symptoms other

187 than sore throat, or reported sore throat. Individuals who reported a sore throat and cough as co-

symptoms were placed in the second category. Among the analytes with \geq 80% overall

189 detectability, the median cytokine levels were not significantly higher among convalescent

190 individuals who were symptomatic, asymptomatic, or reporting sore throat (Fig 4). Among the

analytes with <80% overall detectability, the percent detectability analytes in individuals

reporting sore throat (no cough) versus other symptoms were not significantly different (Fig 5).

193

194 Figure 4. Cytokine levels by symptom group

195

196 Figure 5. Detectability of cytokine markers by response panel and symptom group

197

198 **Discussion**

199	This study demonstrates associations between symptom presentation and antibody assay
200	reactivity. Assay reactivity appears to be consistent across symptoms, suggesting that antibodies
201	produced by convalescent individuals share a similar responsiveness to different parts of the
202	virus regardless of symptom presentation. In addition to hospitalization and male sex, reporting
203	cough appeared to be predictive of a seropositive result, suggesting that these individuals may be
204	more likely to generate a robust antibody response. Conversely, sore throat and no symptoms
205	were associated with a seronegative result.
206	Previous studies have demonstrated higher antibody titers in individuals exhibiting more
207	symptomatic disease. ^{4,18} Our results are complementary to these findings, given that
208	asymptomatic convalescent individuals were significantly associated with a seronegative result.
209	Strikingly, our study demonstrates the single symptom of sore throat being associated with a
210	seronegative result. This finding has not been demonstrated in prior studies investigating
211	COVID-19 symptoms and antibody reactivity. However, the lower and upper respiratory tract
212	has shown to differ in their mechanisms of immunity, with sore throat being a presenting
213	symptom of an upper respiratory tract infection. ¹⁹⁻²¹
214	Studies regarding influenza have demonstrated robust IgG responses to be more indicative of
215	a lower respiratory tract infection. ^{22,23} Moreover, others have suggested that the progress of
216	COVID-19 disease, when confined to the upper respiratory tract, typically appears to resolve
217	with minimal to no symptoms. ²⁴ This literature may serve as a potential explanation as to why
218	convalescent individuals in this study reporting no symptoms and sore throat generate fewer IgG

antibodies. Alternatively, a strong innate immune response may serve to effectively combat the

virus in these convalescent individuals, thus not necessitating a robust antibody response;
however, our cytokine and chemokine data do not support this rationalization. Given that a
median of 30 days had passed since symptom resolution in this subject pool at the time of blood
collection, it is possible that cytokine and chemokine levels may have declined to their basal
levels.²⁵

225 Our study had several limitations. First, capture of clinical symptoms was based on self-226 reporting rather than review of the patients' medical records. Individuals reporting a certain 227 symptom may have experienced a more severe presentation than others reporting the same 228 symptom, which was not captured by this dataset and may have influenced antibody production. 229 Second, samples were obtained a median of 49 days after participants had PCR positive results 230 and 30 days post symptom resolution. Antibody levels may have declined at the time of sample 231 collection; furthermore, samples were collected at only one timepoint and inferences about 232 persistently high titers of antibodies based on symptom cannot be made. 233 In this cohort of known SARS-CoV-2 infected individuals, we found a strong association 234 between cough and antibody response. Conversely, a sore throat was strongly associated with a 235 lack of antibody response to SARS-CoV-2 infection. Future studies could test for IgA levels in 236 nasal or throat samples to evaluate whether a robust mucosal IgA response is associated with 237 certain clinical presentations of COVID-19. Immune factors other than antibodies and our panel 238 of human cytokines may also be evaluated to better characterize the immune responses generated 239 by individuals exhibiting particular symptomatology.

240

Acknowledgments The authors would like to thank the participants who donated their
plasma and the study trial staff, without whom this investigation could not be conducted.

243 **References**

- 1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-
- 245 CoV-2 pneumonia in wuhan, china: A single-centered, retrospective, observational study. *The*
- 246 Lancet Respiratory Medicine. 2020;8(5):475-481.
- 247 2. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2
- infection in health care workers. *New England Journal of Medicine*. 2021;384(6):533-540.
- 249 3. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- 250 asymptomatic SARS-CoV-2 infection. *Nature Medicine 2021 27:11*. 2021;27(11):2032-2040.
- 4. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2 antibody titers track with
- functional humoral stability. *Nature Communications 2021 12:1.* 2021;12(1):1-8.
- 5. Klein SL, Pekosz A, Park H, et al. Sex, age, and hospitalization drive antibody responses in a
- 254 COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141-6150.
- 255 Accessed Jan 7, 2022. doi: 10.1172/JCI142004.
- 256 6. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic
- 257 SARS-CoV-2 infections. *Nature Medicine 2020 26:8*. 2020;26(8):1200-1204.
- 258 7. Grossberg AN, Koza LA, Ledreux A, et al. A multiplex chemiluminescent immunoassay for
- 259 serological profiling of COVID-19-positive symptomatic and asymptomatic patients. *Nature*
- 260 *Communications 2021 12:1.* 2021;12(1):1-11.

- 261 8. Caturegli G, Materi J, Howard BM, Caturegli P. Clinical validity of serum antibodies to
- 262 SARS-CoV-2. Ann Intern Med. 2020;173(8):614-622.
- 263 <u>https://www.acpjournals.org/doi/10.7326/M20-2889</u>. Accessed Jan 20, 2022. doi: 10.7326/M20264 2889.
- 265 9. Smith DR. Herd immunity. *Veterinary Clinics of North America: Food Animal Practice*.
- 266 2019;35(3):593-604.
- 10. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by
- 268 SARS-CoV-2: A comparative evolutionary study. *The Lancet Microbe*. 2021;2(12):e666-e675.
- 269 11. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection
- 270 with SARS-CoV-2 after COVID-19 vaccination kentucky, May–June 2021. MMWR.
- 271 Morbidity and Mortality Weekly Report. 2021;70(32):1081-1083.
- 12. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially
- available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high
- 274 neutralizing titers. *Journal of Clinical Microbiology*. 2020.
- 275 <u>https://journals.asm.org/doi/abs/10.1128/JCM.02257-20</u>. Accessed Jan 11, 2022. doi:
- 276 10.1128/JCM.02257-20.
- 13. Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in
- 278 COVID-19 patients and convalescent plasma donors. *The Journal of Infectious Diseases*.
- 279 2020;222(12):1974-1984.

- 280 14. EUROIMMUN US. Anti-SARS-CoV-2 ELISA (IgG) instruction for use.
- 281 https://www.fda.gov/media/137609/download. Updated 2020.
- 282 15. Healgen. COVID-19 IgG/IgM rapid test cassette (whole blood/serum/plasma) instruction for
- use. https://www.fda.gov/media/138438/download. Updated 2020.
- 284 16. Bio-Rad Laboratories. Platelia SARS-CoV-2 total ab. . Updated 2020.
- 285 17. Bonny TS, Patel EU, Zhu X, et al. Cytokine and chemokine levels in coronavirus disease
- 286 2019 convalescent plasma. Open Forum Infectious Diseases. 2021;8(2).
- 18. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
- 288 COVID-19. Nature Medicine 2020 26:6. 2020;26(6):845-848.
- 289 19. Hodge LM, Simecka JW. Role of upper and lower respiratory tract immunity in resistance to
- 290 mycoplasma respiratory disease. *The Journal of Infectious Diseases*. 2002;186(2):290-294.
- 20. Subbarao K, Mahanty S. Respiratory virus infections: Understanding COVID-19. *Immunity*.
 2020;52(6):905.
- 293 21. Thomas M, Bomar PA. Upper respiratory tract infection. *Medscape*. 2021:1-18.
- 294 22. Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of
- influenza viral infection in the murine respiratory tract. *The Journal of Immunology*.
- 296 2004;173(3):1978-1986.
- 297 23. Ito R, Ozaki YA, Yoshikawa T, et al. Roles of anti-hemagglutinin IgA and IgG antibodies in
- 298 different sites of the respiratory tract of vaccinated mice in preventing lethal influenza

- 299 pneumonia. Vaccine. 2003;21(19):2362-2371.
- 300 https://www.sciencedirect.com/science/article/pii/S0264410X03000781. Accessed Jan 12, 2022.
- 301 doi: 10.1016/S0264-410X(03)00078-1.
- 302 24. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal immunity in COVID-19: A
- 303 neglected but critical aspect of SARS-CoV-2 infection. *Frontiers in Immunology*. 2020;11:3221.
- 304 25. Whiteside TL. Cytokines and cytokine measurements in a clinical laboratory. *Clin Diagn Lab*
- 305 Immunol. 1994;1(3):257-260. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC368245/.
- 306 Accessed Jan 20, 2022.

307











